Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M94.4Revenue (TTM) $M--Net Margin (%)--Altman Z-Score-33.1
Enterprise Value $M94.7EPS (TTM) $-0.6Operating Margin %--Piotroski F-Score2
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %-5.8Quick Ratio1.6Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %5.0Current Ratio1.6Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-148.2Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-291.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M35.6ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with GALT

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

GALT is held by these investors:



GALT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ZUCCONI THEODORE DANIELDirector 2017-05-23Buy1,000$2.2716.74view
CZIRR JAMES CDirector 2016-04-20Sell44,312$1.6758.68view
10X Fund, L.P.10% Owner 2016-04-20Sell44,312$1.6758.68view
10X Fund, L.P.10% Owner 2016-04-20Sell44,312$1.6560.61view
CZIRR JAMES CDirector 2016-04-20Sell44,312$1.6560.61view
Greenberg ArthurDirector 2016-01-05Buy1,666$1.7254.07view
AMELIO GILBERT FDirector 2015-11-30Sell100$2.126.19view
TRABER PETER GPresident & CEO 2015-08-12Buy2,000$232.5view
TRABER PETER GPresident & CEO 2015-06-01Buy4,000$2.534.74view
FREEMAN KEVIN DDirector 2015-06-01Buy2,083$2.7-1.85view

Press Releases about GALT :

Quarterly/Annual Reports about GALT:

News about GALT:

Articles On GuruFocus.com
Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Ea Nov 17 2017 
Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Ea Nov 13 2017 
Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Anti-Fibrotic Drug Development Su Nov 13 2017 
Galectin Therapeutics Reports 2017 Third Quarter Financial Results and Provides Business Update Nov 07 2017 
Galectin Therapeutics to Present Clinical Data at The Liver Meeting® 2017 Demonstrating the Abili Oct 20 2017 
Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Conference for NASH Summit Europe Sep 25 2017 
Galectin Therapeutics Receives Notice of Chinese Allowance to Grant a Key Patent for Composition of Sep 12 2017 
Galectin Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference Sep 05 2017 
Clarification: Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Busi Aug 18 2017 
Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update Aug 14 2017 
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK